Cerebrolysin reverses hippocampal @entity194 in a XXXX model of @entity6 .

@entity2187 @entity6 @entity19 @entity3839 @entity4778 @entity194 @entity3918 @entity4854 @entity413
UNASSIGNED: The animal model of @entity3839 -induced @entity6 ( @entity6 ) is used to study neuronal and behavioral changes produced by an increase in blood- @entity413 levels. Our previous report showed that chronic @entity3839 administration induced @entity194 of dendritic morphology of pyramidal neurons of the @entity4778 dorsal hippocampus. In addition, we showed that Cerebrolysin (Cbl), a neurotrophic peptide mixture, reduces the @entity194 in animal models of aging. This study aimed to determine whether Cbl was capable of reducing behavioral and neuronal alterations, after 6 weeks of @entity4854 in @entity19 ( @entity3839 -induced @entity6 ). The levels of @entity413 in the blood were evaluated before and after @entity3839 administration and only animals with more than 240 mg/dL of blood-levels of @entity413 were used. After @entity3839 treatment, the @entity19 received 6 weeks of Cbl, locomotor activity was measured and dendritic morphological changes were evaluated using Golgi-Cox stain procedure, and analyzed by the Sholl method. In @entity19 treated with @entity3839 there was a clear reduction in the dendritic length of pyramidal neurons of the @entity4778 and granular cells of the dental gyrus of the dorsal hippocampus. Interestingly, @entity2187 reversed the morphological changes induced by @entity3839 . Our results extend the list of abnormal morphological changes detected in this model of @entity3918 , and support the possibility that Cbl may have beneficial effects in the management of brain alterations induced by @entity3918 . This article is protected by copyright. All rights reserved.
